LV12260A - Piridazino [4,5-b]-hinolina-5-oksida atvasinajumi to iegusana un to izmantosana par glicina antagonistiem - Google Patents

Piridazino [4,5-b]-hinolina-5-oksida atvasinajumi to iegusana un to izmantosana par glicina antagonistiem

Info

Publication number
LV12260A
LV12260A LV990014A LV990014A LV12260A LV 12260 A LV12260 A LV 12260A LV 990014 A LV990014 A LV 990014A LV 990014 A LV990014 A LV 990014A LV 12260 A LV12260 A LV 12260A
Authority
LV
Latvia
Prior art keywords
pyridazino
quinolin
derivatives
oxide
glycine antagonists
Prior art date
Application number
LV990014A
Other languages
English (en)
Other versions
LV12260B (lv
Inventor
Wojciech Danysz
Markus Gold
Ivars Kalvinsh
Christopher Graham Rap Parsons
Irene Piskunova
Eugene Rozhkov
Original Assignee
Merz & Co Gmbh & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz & Co Gmbh & Co filed Critical Merz & Co Gmbh & Co
Publication of LV12260A publication Critical patent/LV12260A/lv
Publication of LV12260B publication Critical patent/LV12260B/lv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
LVP-99-14A 1996-07-25 1999-01-22 Piridazino [4,5-B]-hinolīna-5-oksīda atvasinājumi, to iegūšana un to izmantošana par glicīnaantagonistiem LV12260B (lv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/686,346 US5776935A (en) 1996-07-25 1996-07-25 Pyrido-phtalazin diones and their use against neurological disorders associated with excitotoxicity and malfunctioning of glutamatergic neurotransmission
PCT/EP1997/004057 WO1998004556A1 (en) 1996-07-25 1997-07-25 Pyridazino [4,5-b]-quinoline 5-oxide derivatives, their preparation and their use as glycine antagonists

Publications (2)

Publication Number Publication Date
LV12260A true LV12260A (lv) 1999-04-20
LV12260B LV12260B (lv) 1999-08-20

Family

ID=24755940

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-99-14A LV12260B (lv) 1996-07-25 1999-01-22 Piridazino [4,5-B]-hinolīna-5-oksīda atvasinājumi, to iegūšana un to izmantošana par glicīnaantagonistiem

Country Status (31)

Country Link
US (1) US5776935A (lv)
EP (1) EP0931081B1 (lv)
JP (1) JP3595342B2 (lv)
KR (1) KR100598206B1 (lv)
CN (1) CN1093860C (lv)
AR (1) AR004158A1 (lv)
AT (1) ATE224894T1 (lv)
AU (1) AU719993B2 (lv)
BR (1) BR9710569A (lv)
CA (1) CA2261923C (lv)
CZ (1) CZ289293B6 (lv)
DE (1) DE69715893T2 (lv)
DK (1) DK0931081T3 (lv)
EA (1) EA001711B1 (lv)
ES (1) ES2180041T3 (lv)
FI (1) FI112946B (lv)
GE (1) GEP20022801B (lv)
HK (1) HK1020193A1 (lv)
HU (1) HU223780B1 (lv)
IL (1) IL128225A (lv)
LT (1) LT4591B (lv)
LV (1) LV12260B (lv)
NO (1) NO310820B1 (lv)
PL (1) PL189572B1 (lv)
PT (1) PT931081E (lv)
SI (1) SI9720048B (lv)
SK (1) SK283536B6 (lv)
TW (1) TW402605B (lv)
UA (1) UA63911C2 (lv)
WO (1) WO1998004556A1 (lv)
ZA (1) ZA976612B (lv)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030176435A1 (en) * 2002-12-17 2003-09-18 Brown Dean Gordon Compounds and methods for the treatment of pain
US6444702B1 (en) 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
AU2002329799B2 (en) * 2001-08-20 2007-03-15 Maiken Nedergaard Treatment of glial tumors with glutamate antagonists
EP1298581A1 (fr) * 2001-09-27 2003-04-02 C.S.E.M. Centre Suisse D'electronique Et De Microtechnique Sa Procédé et dispositif pour calculer les valeurs des neurones d'un réseau neuronal
US7037524B2 (en) * 2001-10-03 2006-05-02 Herbalscience, Llc Oral delivery of a botanical
US7001620B2 (en) 2001-10-03 2006-02-21 Herbal Science, Llc Kavalactone product
US20050069596A1 (en) * 2001-10-03 2005-03-31 Gow Robert T. Compositions and methods comprising kava and anti-anxiety compounds
US7029707B2 (en) * 2001-10-03 2006-04-18 Herbalscience, Llc Method of producing a processed kava product having an altered kavalactone distribution and processed kava products produced using the same
US7105185B2 (en) 2001-10-03 2006-09-12 Herbalscience, Llc Kavalactone profile
US7291352B2 (en) 2001-10-03 2007-11-06 Herbalscience Llc Methods and compositions for oral delivery of Areca and mate' or theobromine
US20050037025A1 (en) * 2002-10-03 2005-02-17 Gow Robert T. Methods and compositions comprising kava and mate' or theobromine
US20040082543A1 (en) * 2002-10-29 2004-04-29 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
US7294353B2 (en) * 2003-10-24 2007-11-13 Herbalscience, Llc Methods and compositions comprising ilex
US7279184B2 (en) * 2003-10-24 2007-10-09 Herbalscience, Llc Methods and compositions comprising Ilex
US20060280790A1 (en) * 2005-04-08 2006-12-14 Ju Tzuchi R Pharmaceutical formulations
KR20100063087A (ko) * 2007-09-20 2010-06-10 코텍스 파마슈티칼스, 인크. 글루타메이트 시냅스 반응 향상을 위한 3-치환된 1,2,3-트리아진-4-온 및 3-치환된 1,3-피리미디논
EP2264035A1 (en) * 2009-06-04 2010-12-22 Merz Pharma GmbH & Co. KGaA Glycine B antagonists
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
CN110996948A (zh) 2017-06-12 2020-04-10 格莱泰施有限责任公司 用nmda拮抗剂和d2/5ht2a或选择性5ht2a拮抗剂治疗抑郁症
USD895157S1 (en) 2018-03-06 2020-09-01 IsoTruss Indsutries LLC Longitudinal beam
CN109912503B (zh) * 2019-04-01 2022-04-08 江南大学 一种2,3-二酰基喹啉类化合物的合成方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9208511D0 (en) * 1991-05-09 1992-06-03 Ici Plc Compounds
US5597922A (en) * 1994-07-29 1997-01-28 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Glycine receptor antagonist pharmacophore

Also Published As

Publication number Publication date
AU4296997A (en) 1998-02-20
NO990306D0 (no) 1999-01-22
EP0931081B1 (en) 2002-09-25
JP2000515872A (ja) 2000-11-28
CN1228778A (zh) 1999-09-15
PL189572B1 (pl) 2005-08-31
NO310820B1 (no) 2001-09-03
BR9710569A (pt) 1999-08-17
NO990306L (no) 1999-03-15
SK10399A3 (en) 2000-01-18
WO1998004556A1 (en) 1998-02-05
DE69715893D1 (de) 2002-10-31
JP3595342B2 (ja) 2004-12-02
CA2261923A1 (en) 1998-02-05
EP0931081A1 (en) 1999-07-28
DE69715893T2 (de) 2003-01-30
HUP9903104A2 (hu) 2000-03-28
DK0931081T3 (da) 2003-01-27
AU719993B2 (en) 2000-05-18
AR004158A1 (es) 1998-11-04
SI9720048B (sl) 2002-02-28
GEP20022801B (en) 2002-09-25
IL128225A0 (en) 1999-11-30
EA199900161A1 (ru) 1999-10-28
KR100598206B1 (ko) 2006-07-07
FI990134A0 (fi) 1999-01-25
FI112946B (fi) 2004-02-13
CZ2019997A3 (cs) 1999-09-15
CZ289293B6 (cs) 2001-12-12
SK283536B6 (sk) 2003-09-11
ATE224894T1 (de) 2002-10-15
HU223780B1 (hu) 2005-01-28
HUP9903104A3 (en) 2000-04-28
PL331323A1 (en) 1999-07-05
ZA976612B (en) 1998-02-10
US5776935A (en) 1998-07-07
TW402605B (en) 2000-08-21
LT99007A (en) 1999-07-26
LV12260B (lv) 1999-08-20
UA63911C2 (uk) 2004-02-16
PT931081E (pt) 2003-02-28
LT4591B (lt) 1999-12-27
HK1020193A1 (en) 2000-03-31
IL128225A (en) 2005-09-25
CA2261923C (en) 2006-01-24
EA001711B1 (ru) 2001-06-25
KR20000029568A (ko) 2000-05-25
SI9720048A (sl) 1999-12-31
ES2180041T3 (es) 2003-02-01
FI990134A (fi) 1999-03-24
CN1093860C (zh) 2002-11-06

Similar Documents

Publication Publication Date Title
LV12260A (lv) Piridazino [4,5-b]-hinolina-5-oksida atvasinajumi to iegusana un to izmantosana par glicina antagonistiem
EE9800459A (et) Spiro-piperidiini derivaadid ja nende kasutamine terapeutiliste toimeainetena
HUP9901630A3 (en) Indole-2,3-dione-3-oxime derivatives as antagonists of excitatory amino acids, preparation and use thereof
IL126476A0 (en) Aminoisoquinolines and aminothienopyridine derivatives and their use as anti-inflammatory agents
NO991132D0 (no) 3-Substituerte pyrido[4',3',:4,5]tieno[2,3-D]pyrimidin-derivater, fremstilling og anvendelse derav
NO971668L (no) Lyofilisat av lipid-kompleks av vannuopplöselige camptotekiner
EE03830B1 (et) 1H-pürido[3,4-b]indool-4-karboksamiidi derivaadid, nende valmistamismeetodid ja kasutamine raviks
IT8948430A0 (it) Composti tripeptidici e loro uso farmaceutico come immuno-modulatori
FI951726A (fi) Boronihappopeptidijohdannaisia, niiden valmistus ja käyttö synteesivälituotteina
ITMI941112A0 (it) Alcaloidi da mappia foetida, loro uso e formulazioni che li contengono
LV12188A (lv) 1,4-Dihidro-1,4-diokso-1H-naftalina triciklisku atvasinajumu pielietojums jaunu savienojumu iegusanai un to izmantosana terapija
DE69514315D1 (de) AZABICYCLOALKYLDERIVATE VON IMIDAZO[1,5-a]INDOL-3-ONE ALS 5HT3 ANTAGONISTEN
ITFI950044A0 (it) Composti biciclici, loro preparazione ed uso in composizioni farmaceutiche
DE69707293T2 (de) Pyrrolo(3,2-c)chinolin-derivate
DE69733897D1 (de) HERSTELLUNG VON [1S-[1A,2B,3B,4(S*)]]-4-[7-[[1-(3-CHLOR-2-THIENYL)METHYL]PROPYL]AMINO]-3H-IMIDAZO[4,5-b]PYRIDIN-3-YL]-N-ETHYL-2,3-DIHYDROXYCYCLOPENTANCARBOXAMID
ITMI931897A0 (it) 1,3,4- benzotriazepin-554h)-one e procedimento per la loro preparazione
FR2751970B1 (fr) Derives d'acide 6,7,8,9-tetrahydro-5h-imidazo[1,2-a]azepine- 3-acetique, leur preparation et leur application en therapeutique
ITFI920146A1 (it) Proteine funzionalizzate e loro uso per la preparazione di traccianti coniugati
FR2783828B1 (fr) Derives d'acide 5,6-dihydro-4h-imidazo[1,2-a][1] benzazepine -1-acetique, leur preparation et leur application en therapeutique
FI962621A (fi) Virustenvastaisten 4,5,6,7-tetrahydro-imidatso/4,5,1-jk//1,4/bentsodiatsepiini-2-oni ja -2-tionijohdannaisten valmistuksessa välituotteina käyttökelpoisia yhdisteitä
IL152921A0 (en) Preparation of [1s-[alpha, 2beta, 3beta, 4alpha(s*)]]-4-[7-[[1-3-chloro-2-thienyl) methyl] propyl] amino]-3h-imidazo[4,5-b]pyridin-3-yl-]-n-ethyl-2, 3 dihydroxycyclopentanecarboxamide